Roche strikes an €87.5M discovery deal with Confo; Onconova out-licenses preclinical drug to China's HanX
→ Belgian biotech Confo Therapeutics is getting some significant support from Roche. The pharma giant is supplying €6 million over the next 30 months to get a collaboration working on GPCR drugs for neurological and development disorders. If it works out, there’s another €81.5 million for milestones.
→ Onconova is licensing and collaborating on a preclinical dual inhibitor with HanX Biopharmaceuticals, which will fund all the studies required for IND approvals in exchange for commercialization rights in Greater China. The product, ON 123300, targets both CDK4/6 and ARK5, thereby overcoming the limitations of current CDK 4/6 inhibitors that must be used in combination with other drugs. The partners are hoping that data from the Chinese studies, which will comply with American standards, can be used in the US IND as well. On its side of the deal, Onconova receives an upfront payment, regulatory and commercial milestone payments, along with royalties on Chinese sales. “We remain focused on our later stage rigosertib clinical development programs in MDS with near term milestones, and look forward to a close collaboration with HanX as we leverage their strong expertise in drug development and commercialization,” Onconova CEO Ramesh Kumar said in a statement.
→ South San Francisco-based Second Genome says it has successfully completed a Phase I study in healthy volunteers for its lead therapeutic candidate, SGM-1019, which it describes as a first-in-class oral drug for NASH. A Phase II is expected to start in mid-2018.